PSS13 COST-EFFECTIVE ANALYSIS OF PEGAPTANIB (MACUGEN) AS COMPARED WITH RANIBIZUMAB (LUCENTIS) FOR TREATING IN AGE-RELATED MACULAR DEGENERATION (AMD)
May 1, 2008, 00:00
10.1016/S1098-3015(10)70908-6
https://www.valueinhealthjournal.com/article/S1098-3015(10)70908-6/fulltext
Title :
PSS13 COST-EFFECTIVE ANALYSIS OF PEGAPTANIB (MACUGEN) AS COMPARED WITH RANIBIZUMAB (LUCENTIS) FOR TREATING IN AGE-RELATED MACULAR DEGENERATION (AMD)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)70908-6&doi=10.1016/S1098-3015(10)70908-6
First page :
Section Title :
Open access? :
No
Section Order :
665